Mindmed joins clinical trials transformation initiative

New york, oct. 13, 2021 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (de: mmq) (the "company"), a leading biotech company developing psychedelic-inspired therapies, has joined the clinical trials transformation initiative (ctti) to contribute in developing and driving adoption of practices that increase the quality and efficiency of clinical trials. mindmed joins ctti as one of approximately 80 member organizations interested in advancing higher quality clinical trials and accelerating the path to new therapeutics and other medical products.
MNMD Ratings Summary
MNMD Quant Ranking